Alzheimer's disease (AD), a neurodegenerative condition and major subtype of dementia, is often preceded by mild cognitive impairment (MCI), a transitional stage before dementia. While cerebrospinal fluid (CSF) biomarkers are widely used for diagnosing AD and MCI, blood-based biomarkers offer the advantage of easier accessibility. This study aimed to compare blood levels of nine biomarkers among healthy controls, patients with MCI, and those with dementia, and to evaluate their potential for predicting AD progression.
Objective
The aim of our study was to study biomarkers in three groups of elderly people with varying degrees of cognitive decline.
Methods
The study included 234 participants aged 65 and older with dementia, MCI, or no cognitive impairment. Cognitive function was assessed using the Mini-Mental State Examination scale. Plasma levels of nine biomarkers, including amyloid-β40 (Aβ40), amyloid-β42 (Aβ42), KLK-6, NCAM-1, FGF-21, neurogranin, Tau, pTau181, and TDP-43, were measured by multiplex analysis.
Results
Aβ42 levels were higher in the MCI group compared to controls (p = 0.002) and in dementia patients compared to those with MCI (p = 0.018). TDP-43 and neurogranin levels were elevated in dementia patients compared to both the MCI group (p < 0.05 and p < 0.01, respectively) and controls (p < 0.05 and p < 0.001, respectively). Neurogranin levels were also higher in the MCI group compared to controls (p < 0.001) and significantly differed between MCI and dementia (p = 0.003).
Conclusions
Aβ42, TDP-43, and neurogranin show potential as blood-based biomarkers for cognitive decline and may provide insight into the pathogenesis of neurodegeneration.
World Health Organization. Global status report on the public health response to dementia. World Health Organization, https://iris.who.int/handle/10665/344701 (2021, accessed 18 December 2024).
2.
2024 Alzheimer’s disease facts and figures. Alzheimers Dement2024; 20: 3708–3821.
3.
GustavssonANortonNFastT, et al.Global estimates on the number of persons across the Alzheimer’s disease continuum. Alzheimers Dement2023; 19: 658–670.
RajanKBWeuveJBarnesLL, et al.Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060). Alzheimers Dement2021; 17: 1966–1975.
6.
MorozovaAZorkinaYAbramovaO, et al.Neurobiological highlights of cognitive impairment in psychiatric disorders. Int J Mol Sci2022; 23: 1217.
7.
BraakHThalDRGhebremedhinE, et al.Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol2011; 70: 960–969.
8.
KeppKPRobakisNKHøilund-CarlsenPF, et al.The amyloid cascade hypothesis: an updated critical review. Brain2023; 146: 3969–3990.
9.
ParoniGBiscegliaPSeripaD. Understanding the amyloid hypothesis in Alzheimer’s disease. J Alzheimers Dis2019; 68: 493–510.
10.
HardyJAllsopD. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci1991; 12: 383–388.
11.
OlssonBLautnerRAndreassonU, et al.CSF And blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol2016; 15: 673–684.
12.
McGrowderDAMillerFVazK, et al.Cerebrospinal fluid biomarkers of Alzheimer's disease: current evidence and future perspectives. Brain Sci2021; 11: 215.
13.
BarthélemyNRLiYJoseph-MathurinN, et al.A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nat Med2020; 26: 398–407.
14.
DuboisBFeldmanHHJacovaC, et al.Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol2014; 13: 614–629.
15.
SimrénJLeuzyAKarikariTK, et al.The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer’s disease. Alzheimers Dement2021; 17: 1145–1156.
16.
MattssonNLönneborgABoccardiM, et al.Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging2017; 52: 196–213.
17.
LafirdeenASMCognatESabiaS, et al.Biomarker profiles of Alzheimer’s disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau. PLoS One2019; 14: e0217026.
18.
SunBLLiWWZhuC, et al.Clinical research on Alzheimer’s disease: progress and perspectives. Neurosci Bull2018; 34: 1111–1118.
19.
BlennowKZetterbergH. The past and the future of Alzheimer’s disease fluid biomarkers. J Alzheimers Dis2018; 62: 1125–1140.
20.
Álvarez-SánchezLPeña-BautistaCFerré-GonzálezL, et al.Early Alzheimer’s disease screening approach using plasma biomarkers. Int J Mol Sci2023; 24: 14151.
21.
BarthélemyNRSalvadóGSchindlerSE, et al.Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med2024; 30: 1085–1095.
22.
AschenbrennerAJLiYHensonRL, et al.Comparison of plasma and CSF biomarkers in predicting cognitive decline. Ann Clin Transl Neurol2022; 9: 1739–1751.
23.
Díez-GuerraFJ. Neurogranin, a link between calcium/calmodulin and protein kinase C signaling in synaptic plasticity. IUBMB Life2010; 62: 597–606.
24.
GriffithsJGrantSGN. Synapse pathology in Alzheimer's disease. Semin Cell Dev Biol2023; 139: 13–23.
25.
ThorsellABjerkeMGobomJ, et al.Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer’s disease. Brain Res2010; 1362: 13–22.
26.
LiuWLinHHeX, et al.Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer’s disease and mild cognitive impairment. Transl Psychiatry2020; 10: 125.
27.
PorteliusEOlssonBHöglundK, et al.Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol2018; 136: 363–376.
28.
LaferrièreFManieckaZPérez-BerlangaM, et al.TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nat Neurosci2019; 22: 65–77.
29.
WeskampKBarmadaSJ. TDP43 And RNA instability in amyotrophic lateral sclerosis. Brain Res2018; 1693: 67–74.
30.
WilsonRSYuLTrojanowskiJQ, et al.TDP-43 pathology, cognitive decline, and dementia in old age. JAMA Neurol2013; 70: 1418–1424.
31.
NagSYuLCapuanoAW, et al.Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer’s disease. Ann Neurol2015; 77: 942–952.
32.
De BoerEMJOrieVKWilliamsT, et al.TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry2020; 92: 86–95.
33.
ChenGFXuTHYanY, et al.Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin2017; 38: 1205–1235.
34.
RiekR. The three-dimensional structures of amyloids. Cold Spring Harb Perspect Biol2017; 9: a023572.
35.
DawkinsESmallDH. Insights into the physiological function of the β-amyloid precursor protein: beyond Alzheimer’s disease. J Neurochem2014; 129: 756–769.
36.
MorleyJEFarrSANguyenAD, et al.Editorial: what is the physiological function of amyloid-beta protein?J Nutr Health Aging2019; 23: 225–226.
37.
BrothersHMGosztylaMLRobinsonSR. The physiological roles of amyloid-β peptide hint at new ways to treat Alzheimer’s disease. Front Aging Neurosci2018; 10: 118.
38.
WangLEomKKwonT. Different aggregation pathways and structures for Aβ40 and Aβ42 peptides. Biomolecules2021; 11: 198.
39.
ReissABArainHASteckerMM, et al.Amyloid toxicity in Alzheimer’s disease. Rev Neurosci2018; 29: 613–627.
40.
ImDChoiTS. Distinctive contribution of two additional residues in protein aggregation of Aβ42 and Aβ40 isoforms. BMB Rep2024; 57: 263–272.
41.
RajasekharKChakrabartiMGovindarajuT. Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer’s disease. Chem Commun (Camb)2015; 51: 13434–13450.
42.
Cárdenas-AguayoMdCSilva-LuceroMdCCortes-OrtizM, et al.Physiological role of amyloid beta in neural cells: the cellular trophic activity. In: Neurochemistry. London: IntechOpen, 2014, pp.1–26.
43.
FuLSunYGuoY, et al.Comparison of neurotoxicity of different aggregated forms of Aβ40, Aβ42 and Aβ43 in cell cultures. J Pept Sci2017; 23: 245–251.
44.
NirmalrajPNListJBattacharyaS, et al.Complete aggregation pathway of amyloid β (1-40) and (1-42) resolved on an atomically clean interface. Sci Adv2020; 6: eaaz6014.
45.
SánchezLMadurgaSPukalaT, et al.Aβ40 and Aβ42 amyloid fibrils exhibit distinct molecular recycling properties. J Am Chem Soc2011; 133: 6505–6508.
46.
KolarovaMGarcía-SierraFBartosA, et al.Structure and pathology of tau protein in Alzheimer disease. Int J Alzheimers Dis2012; 2012: 731526.
47.
ClevelandDWHwoSYKirschnerMW. Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly. J Mol Biol1977; 116: 227–247.
48.
QiHCantrelleFXBenhelli-MokraniH, et al.Nuclear magnetic resonance spectroscopy characterization of interaction of tau with DNA and its regulation by phosphorylation. Biochemistry2015; 54: 1525–1533.
49.
AvilaJJiménezJSSayasCL, et al.Tau structures. Front Aging Neurosci2016; 8: 262.
50.
ReddyPH. Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer’s disease. Brain Res2011; 1415: 136–148.
51.
HymanBTAugustinackJCIngelssonM. Transcriptional and conformational changes of the tau molecule in Alzheimer’s disease. Biochim Biophys Acta2005; 1739: 150–157.
52.
RawatPSeharUBishtJ, et al.Phosphorylated tau in Alzheimer’s disease and other tauopathies. Int J Mol Sci2022; 23: 12841.
53.
GuoTNobleWHangerDP. Roles of tau protein in health and disease. Acta Neuropathol2017; 133: 665–704.
54.
MenesesAKogaSO’LearyJ, et al.TDP-43 pathology in Alzheimer’s disease. Mol Neurodegener2021; 16: 84.
55.
NeumannMSampathuDMKwongLK, et al.Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science2006; 314: 130–133.
56.
ArseniDHasegawaMMurzinAG, et al.Structure of pathological TDP-43 filaments from ALS with FTLD. Nature2022; 601: 139–143.
57.
NonakaTMasuda-SuzukakeMAraiT, et al.Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep2013; 4: 124–134.
58.
HigashiSKabutaTNagaiY, et al.TDP-43 associates with stalled ribosomes and contributes to cell survival during cellular stress. J Neurochem2013; 126: 288–300.
59.
KawaharaYMieda-SatoA. TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc Natl Acad Sci U S A2012; 109: 3347–3352.
60.
AyalaYMZagoPD’AmbrogioA, et al.Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci2008; 121: 3778–3785.
61.
Chen-PlotkinASLeeVMYTrojanowskiJQ. TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol2010; 6: 211–220.
62.
ChangXLTanMSTanL, et al.The role of TDP-43 in Alzheimer’s disease. Mol Neurobiol2016; 53: 3349–3359.
63.
ToméSOVandenbergheROspitalieriS, et al.Distinct molecular patterns of TDP-43 pathology in Alzheimer’s disease: relationship with clinical phenotypes. Acta Neuropathol Commun2020; 8: 61.
64.
BayaniJDiamandisEP. The physiology and pathobiology of human kallikrein-related peptidase 6 (KLK6). Clin Chem Lab Med2011; 50: 211–233.
65.
StefaniniACBda CunhaBRHenriqueT, et al.Involvement of kallikrein-related peptidases in normal and pathologic processes. Dis Markers2015; 2015: 946572.
66.
MellaCFigueroaCDOtthC, et al.Involvement of kallikrein-related peptidases in nervous system disorders. Front Cell Neurosci2020; 14: 166.
67.
SotiropoulouGPampalakisG. Kallikrein-related peptidases: bridges between immune functions and extracellular matrix degradation. Biol Chem2010; 391: 321–331.
68.
BoumaliRUrliLNaimM, et al.Kallikrein-related peptidase’s significance in Alzheimer’s disease pathogenesis: a comprehensive survey. Biochimie2024; 226: 77–90.
69.
GoldhardtOWarnhoffIYakushevI, et al.Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer’s disease and associated with CSF-TAU and FDG-PET. Transl Neurodegener2019; 8: 25.
70.
LukeMPSLeVatteTLO’ReillyAM, et al.Effect of NCAM on aged-related deterioration in vision. Neurobiol Aging2016; 41: 93–106.
71.
RønnLCHartzBPBockE. The neural cell adhesion molecule (NCAM) in development and plasticity of the nervous system. Exp Gerontol1998; 33: 853–864.
72.
DuncanBWMurphyKEManessPF. Molecular mechanisms of L1 and NCAM adhesion molecules in synaptic pruning, plasticity, and stabilization. Front Cell Dev Biol2021; 9: 625340.
73.
SytnykVLeshchyns’kaISchachnerM. Neural cell adhesion molecules of the immunoglobulin superfamily regulate synapse formation, maintenance, and function. Trends Neurosci2017; 40: 295–308.
AgnelloLGambinoCMLo SassoB, et al.Neurogranin as a novel biomarker in Alzheimer’s disease. Lab Med2021; 52: 188–196.
78.
HoffmanLChandrasekarAWangX, et al.Neurogranin alters the structure and calcium binding properties of calmodulin. J Biol Chem2014; 289: 14644–14655.
79.
ZhongLBrownJKramerA, et al.Increased prefrontal cortex neurogranin enhances plasticity and extinction learning. J Neurosci2015; 35: 7503–7508.
80.
ListaSHampelH. Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer’s disease. Expert Rev Neurother2017; 17: 47–57.
81.
CreavinSTWisniewskiSNoel-StorrAH, et al.Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database Syst Rev2016; 2016: CD011145.
82.
FolsteinMFFolsteinSEMcHughPR. Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12: 189–198.
83.
NasreddineZSPhillipsNABédirianV, et al.The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc2005; 53: 695–699.
84.
MufsonEJChenEYCochranEJ, et al.Entorhinal cortex β-amyloid load in individuals with mild cognitive impairment. Exp Neurol1999; 158: 469–490.
85.
PriceJLMorrisJC. Tangles and plaques in nondemented aging and ‘preclinical’ Alzheimer’s disease. Ann Neurol1999; 45: 358–368.
86.
DelabyCEstellésTZhuN, et al.The Aβ1-42/Aβ1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1-42 alone. Alzheimers Res Ther2022; 14: 20.
87.
KimHJParkKWKimTE, et al.Elevation of the plasma Aβ40/Aβ42 ratio as a diagnostic marker of sporadic early-onset Alzheimer’s disease. J Alzheimers Dis2015; 48: 1043–1050.
88.
SchindlerSEPetersenKKSaefB, et al.Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology. Alzheimers Dement2024; 20: 8074–8096.
89.
DevanarayanVDohertyTCharilA, et al.Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer’s disease. Alzheimers Dement2024; 20: 5617–5628.
90.
LeuzyAMattsson-CarlgrenNPalmqvistS, et al.Blood-based biomarkers for Alzheimer’s disease. EMBO Mol Med2022; 14: e14408.
WangZYangJZhuW, et al.The synaptic marker neurogranin as a disease state biomarker in Alzheimer’s disease: a systematic review and meta-analysis. Int J Neurosci2022; 132: 1245–1253.
93.
NeumannM. Molecular neuropathology of TDP-43 proteinopathies. Int J Mol Sci2009; 10: 232–246.
94.
JoMLeeSJeonYM, et al.The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies. Exp Mol Med2020; 52: 1652–1662.
95.
FouldsPMcAuleyEGibbonsL, et al.TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer’s disease and frontotemporal lobar degeneration. Acta Neuropathol2008; 116: 141–146.
96.
ZhangNGuDMengM, et al.TDP-43 is elevated in plasma neuronal-derived exosomes of patients with Alzheimer's disease. Front Aging Neurosci2020; 12: 166.
97.
McAleeseKEWalkerLErskineD, et al.TDP-43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing. Brain Pathol2017; 27: 472–479.
98.
SunLLiWYueL, et al.Blood TDP-43 combined with demographics information predicts dementia occurrence in community non-dementia elderly. J Alzheimers Dis2021; 79: 301–309.
99.
KojimaYKasaiTNotoYI, et al.Amyotrophic lateral sclerosis: correlations between fluid biomarkers of NfL, TDP-43, and tau, and clinical characteristics. PLoS One2021; 16: e0260323.
100.
López-CarboneroJIGarcía-ToledoIFernández-HernándezL, et al.In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use. Transl Neurodegener2024; 13: 29.
101.
CordtsIWachingerAScialoC, et al.TDP-43 proteinopathy specific biomarker development. Cells2023; 12: 597.
102.
SaundersTGunnCBlennowK, et al.Neurogranin in Alzheimer’s disease and ageing: a human post-mortem study. Neurobiol Dis2023; 177: 105991.
103.
PorteliusEZetterbergHSkillbäckT, et al.Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. Brain2015; 138: 3373–3385.
104.
KvartsbergHDuitsFHIngelssonM, et al.Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer’s disease. Alzheimers Dement2015; 11: 1180–1190.
105.
YoongSQLuJXingH, et al.The prognostic utility of CSF neurogranin in predicting future cognitive decline in the Alzheimer’s disease continuum: a systematic review and meta-analysis with narrative synthesis. Ageing Res Rev2021; 72: 101491.
106.
SunXHeadleyADe leon-BenedettiA, et al.CSF Neurogranin levels predict cognitive decline in MCI patients (P4. 185). Neurology2018; 90: P4–185.
107.
FoleyKEWinderZSudduthTL, et al.Alzheimer's disease and inflammatory biomarkers positively correlate in plasma in the UK-ADRC cohort. Alzheimers Dement2024; 20: 1374–1386.
108.
CampbellMRAshrafzadeh-KianSPetersenRC, et al.P-tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status. Alzheimers Dement (Amst)2021; 13: e12190.
109.
BouwmanFHFrisoniGBJohnsonSC, et al.Clinical application of CSF biomarkers for Alzheimer's disease: from rationale to ratios. Alzheimer's Dement2022; 14: e12314.
110.
GeorgakasJEHoweMDThompsonLI, et al.Biomarkers of Alzheimer’s disease: past, present and future clinical use. Biomark Neuropsychiat2023; 8: 100063.
111.
GatchAJDingF. TDP-43 promotes amyloid-beta toxicity by delaying fibril maturation via direct molecular interaction. ACS Chem Neurosci2024; 15: 2936–2953.
112.
ShihYHTuLHChangTY, et al.TDP-43 interacts with amyloid-β, inhibits fibrillization, and worsens pathology in a model of Alzheimer’s disease. Nat Commun2020; 11: 5950.
113.
ChenTBLinKJLinSY, et al.Prediction of cerebral amyloid pathology based on plasma amyloid and tau related markers. Front Neurol2021; 12: 619388.
114.
YunGKimHJKimHG, et al.Association between plasma amyloid-β and neuropsychological performance in patients with cognitive decline. Front Aging Neurosci2021; 13: 736937.
115.
LeePJTsaiCLLiangCS, et al.Biomarkers with plasma amyloid β and tau protein assayed by immunomagnetic reduction in patients with amnestic mild cognitive impairment and Alzheimer’s disease. Acta Neurol Taiwan2022; 31: 53–60.
